Literature DB >> 33057988

The influence of parathyroidectomy on cardiometabolic risk factors in patients with primary hyperparathyroidism: a systematic review and meta-analysis.

Maryam Yavari1, Awat Feizi2, Fahimeh Haghighatdoost3, Azin Ghaffari4, Hassan Rezvanian5.   

Abstract

PURPOSE: Primary hyperparathyroidism (PHPT) is associated with increased risk of cardiovascular morbidity and mortality. We aim to determine whether parathyroidectomy (PTX) can change cardiometabolic risk factors including serum lipids, glycemic parameters, systolic and diastolic blood pressure, C reactive protein (CRP), and body mass index (BMI).
METHODS: MEDLINE, Web of Science, Scopus, and Google Scholar were searched for relevant articles published till June 2020. Fixed-effect or random-effects models were used to estimate the weighted mean difference (WMD) and 95% CI for outcomes where applicable.
RESULTS: In total, 34 studies were eligible to be included in the current meta-analysis. Our results indicated no favorable change in serum triglyceride (n = 13, WMD = -0.06, 95% CI: -0.15, 0.03 mmol/L), total cholesterol (n = 15, WMD = 0.01, 95% CI: -0.14, 0.16 mmol/L), LDL-C (n = 10, WMD = -0.01, 95% CI: -0.17, 0.19 mmol/L), HDL-C (n = 10, WMD = 0.03, 95% CI: -0.001, 0.06 mmol/L), and CRP (n = 5, WMD = 0.82, 95% CI: -0.01, 1.64 mg/L) after PTX in PHPT patients. However, glucose (n = 24, WMD = -0.16, 95% CI: -0.26, -0.06 mmol/L), serum insulin (n = 12, WMD = -1.11, 95% CI: -1.73, -0.49 µIU/mL), systolic (n = 17, WMD = -10.14, 95% CI: -12.27, -8.01 mmHg), and diastolic (n = 16, WMD = -5.21, 95% CI: -7.0, -3.43 mmHg) blood pressures were decreased after PTX, whilst a significant increase was observed in BMI (n = 13, WMD = 0.35, 95% CI: 0.19, 0.51 kg/m2).
CONCLUSIONS: PTX could improve glycemic parameters and blood pressure, without any significant change in serum lipoproteins and CRP.

Entities:  

Keywords:  Blood pressure; Cardiometabolic risk; Dyslipidemia; Glycemic response; Parathyroidectomy; Primary hyperparathyroidism

Year:  2020        PMID: 33057988     DOI: 10.1007/s12020-020-02519-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  56 in total

1.  Association between primary hyperparathyroidism and increased body weight: a meta-analysis.

Authors:  Mark J Bolland; Andrew B Grey; Greg D Gamble; Ian R Reid
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  Insulin sensitivity in normocalcaemic primary hyperparathyroidism.

Authors:  F Tassone; M Maccario; L Gianotti; C Baffoni; M Pellegrino; S Cassibba; F Cesario; G Magro; G Borretta
Journal:  Endocrine       Date:  2013-09-25       Impact factor: 3.633

Review 3.  The diagnosis and management of hypercalcaemia.

Authors:  Salvatore Minisola; Jessica Pepe; Sara Piemonte; Cristiana Cipriani
Journal:  BMJ       Date:  2015-06-02

4.  Primary hyperparathyroidism is one of the three most frequent endocrine disorders, typically diagnosed in the years following menopause and with advancing age.

Authors:  Salvatore Minisola
Journal:  J Endocrinol Invest       Date:  2012-07       Impact factor: 4.256

Review 5.  Primary Hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

6.  The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record.

Authors:  Danielle M Press; Allan E Siperstein; Eren Berber; Joyce J Shin; Rosemarie Metzger; Rosebel Monteiro; Jeff Mino; Warren Swagel; Jamie C Mitchell
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

7.  The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism.

Authors:  M Procopio; G Magro; F Cesario; A Piovesan; A Pia; N Molineri; G Borretta
Journal:  Diabet Med       Date:  2002-11       Impact factor: 4.359

8.  Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers.

Authors:  Parastou Farahnak; Gerd Lärfars; Margareta Sten-Linder; Inga-Lena Nilsson
Journal:  J Clin Endocrinol Metab       Date:  2011-05-18       Impact factor: 5.958

9.  Epidemiology of primary hyperparathyroidism.

Authors:  Bart L Clarke
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

10.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

View more
  1 in total

1.  Effect of Parathyroidectomy on Metabolic Homeostasis in Primary Hyperparathyroidism.

Authors:  Samuel Frey; Raphaël Bourgade; Cédric Le May; Mikaël Croyal; Edith Bigot-Corbel; Nelly Renaud-Moreau; Matthieu Wargny; Cécile Caillard; Eric Mirallié; Bertrand Cariou; Claire Blanchard
Journal:  J Clin Med       Date:  2022-03-02       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.